GLP-1 Drug Tirzepatide Helps Clear Plaque Psoriasis and Shed Pounds, Trial Shows

When you think of psoriasis, you probably picture red, scaly patches on the skin. But for millions of people, the condition goes much deeper. Psoriasis is an autoimmune disease that causes inflammation throughout the body. This inflammation doesn’t just affect the skin — it can also raise the risk for other serious health problems like heart disease, high blood pressure, and unhealthy cholesterol levels. Many people with psoriasis also struggle with excess weight, which makes both the skin symptoms and the hidden health risks even harder to manage.

A new study published in JAMA Dermatology offers fresh hope. Researchers found that adding a drug called tirzepatide (brand name Zepbound) to a standard psoriasis treatment significantly improved skin clearance and helped patients lose weight. The combination approach addressed both the visible signs of psoriasis and the underlying metabolic issues that often come with the disease. Here’s what you need to know about this research, why it matters, and how it might change the way psoriasis is treated in the future.

Understanding Plaque Psoriasis and Its Hidden Risks

Plaque psoriasis is the most common form of the disease, affecting up to 90% of people with psoriasis. It happens when the immune system sends faulty signals that speed up the growth of skin cells. Instead of shedding normally, those cells pile up on the surface, forming thick, itchy, and sometimes painful plaques. The severity of psoriasis is often measured by the Psoriasis Area Severity Index, or PASI. A PASI score of 100 means the skin is completely clear, while lower PASI numbers like 75 or 90 indicate a large reduction in plaques.

But psoriasis is not just a skin problem. Doctors now know that the same inflammation that attacks the skin can also harm blood vessels, the heart, and other organs. This means people with psoriasis are more likely to develop cardiovascular disease — a group of conditions that includes heart attacks and strokes. Psoriasis is considered a cardiovascular risk enhancer, which means having the condition automatically puts someone in a higher risk category for heart problems. On top of that, psoriasis can promote high triglycerides (a type of blood fat) and insulin resistance, both of which contribute to metabolic syndrome and type 2 diabetes. Despite these well-known links, many patients with psoriasis do not get proper screening or treatment for their heart-related risk factors, leading to preventable health problems.

What Are GLP-1 Drugs and Why Might They Help?

GLP-1 receptor agonists are a class of medications that have gained a lot of attention for their ability to treat type 2 diabetes and promote weight loss. Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it works on two different hormone pathways instead of just one. These drugs help the body release more insulin after eating, slow down digestion, and reduce appetite. Over the past few years, GLP-1 drugs have been proven to do more than just control blood sugar and weight. They have received approval for other conditions like obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis (a type of fatty liver disease), and reducing the risk of major cardiovascular events in people with heart disease.

So why would a diabetes and weight-loss drug help with psoriasis? The reasoning is strong. Obesity and metabolic syndrome are two of the most common health issues seen in people with psoriasis and psoriatic arthritis. Excess fat tissue releases inflammatory chemicals that can make psoriasis worse. By helping patients lose weight and improve their metabolic health, GLP-1 drugs may reduce that inflammatory burden. Some research even suggests these medications might have direct anti-inflammatory effects on the immune system, although that idea is still being explored. A recent review of medical charts for 1,500 patients with psoriasis or a related skin condition called hidradenitis suppurativa found that 60% met the criteria for using a GLP-1 drug. Yet, until now, there hasn’t been a rigorous clinical trial testing whether a GLP-1 drug could actually improve psoriasis symptoms when added to standard therapy.

Inside the TOGETHER-PsO Study

The trial, called TOGETHER-PsO, was a phase IIIb study designed to fill that evidence gap. It was an open-label trial, meaning both researchers and patients knew which treatments were being used. The study took place at 72 sites across the United States over 52 weeks. A total of 274 adults with moderate to severe plaque psoriasis took part. All patients were either overweight or had obesity, and many had at least one weight-related health condition. The average age of participants was 46 years, 55% were men, and their average body mass index (BMI) was 39.2, which falls into the obesity range. On average, they had been living with psoriasis for nearly 15 years, and their starting PASI score was 19.7, indicating significant disease.

Participants were randomly divided into two groups. One group received the biologic drug ixekizumab (Taltz), a well-established treatment for moderate to severe plaque psoriasis. The other group received ixekizumab plus tirzepatide. Ixekizumab works by blocking a specific inflammatory protein called interleukin-17A. The researchers wanted to see whether adding tirzepatide would offer extra benefits beyond what ixekizumab could do on its own.

Breaking Down the Key Findings

At 36 weeks into the trial, the results were clear. The study’s primary endpoint — a combination of two goals — showed that 27.1% of patients taking both drugs achieved complete skin clearance (PASI 100) and at least a 10% reduction in body weight. In the group taking ixekizumab alone, only 5.8% met that combined goal. This difference was highly statistically significant (P value less than 0.001), meaning it was not due to chance.

Further results painted an even more detailed picture of the benefits:

• Complete skin clearance: 40.6% of patients in the combination group achieved PASI 100, compared with 29% in the ixekizumab-only group (P equals 0.04).
• Weight loss plus major skin improvement: 79.9% of those receiving tirzepatide reached PASI 75 along with at least a 5% weight loss, versus just 17.9% in the control group (P less than 0.001).
• More weight loss plus skin clearance: 69.2% of the tirzepatide group achieved PASI 75 and at least 10% weight loss, compared to 9.1% of those on ixekizumab alone (P less than 0.001).
• Overall weight reduction: 69% of patients adding tirzepatide lost 10% or more of their body weight, while only 9.1% in the control group did the same (P less than 0.001).

Not every measurement showed a clear winner. When researchers looked at PASI 75 or PASI 90 scores alone — without the weight loss component — the differences between the two groups were not statistically significant. This suggests that the real advantage of adding tirzepatide is the combination of skin improvement and meaningful weight loss, rather than dramatically better skin clearance by itself. Beyond the skin and weight benefits, the study also tracked metabolic health markers. Patients receiving tirzepatide saw significant improvements in triglyceride levels and blood pressure compared to those taking only ixekizumab. These are important wins for long-term heart health.

Safety and Side Effects

The researchers reported no new safety concerns. Side effects related to treatment were more common in the tirzepatide group, with 71% experiencing at least one adverse event, compared to 66.4% in the ixekizumab-only arm. Most of these events were mild to moderate. The most frequently reported issues were gastrointestinal problems — such as nausea, vomiting, or diarrhea — which are well-known effects of GLP-1 drugs. Injection site reactions also occurred in both groups. Serious adverse events happened in 3.6% of the combination group and 6% of the control group. No deaths occurred during the study. The rate of stopping treatment due to side effects was 3.6% for patients on tirzepatide and 1.5% for those on ixekizumab alone.

What Experts Are Saying

The study’s authors, led by Dr. Mark Lebwohl from the Icahn School of Medicine at Mount Sinai in New York City, believe these findings could change the standard of care. They wrote that the results support moving from treating psoriasis alone to a more complete approach that addresses both the immune system and metabolic components of the disease, especially obesity.

The research was also presented at the Society for Investigative Dermatology annual meeting in Chicago, generating strong interest. The authors noted that the trial adds to earlier findings from a companion study called TOGETHER-PsA, which showed that tirzepatide improved psoriatic arthritis, physical function, and quality of

Source: MedPage Today